{"denoms":[{"counts":[{"groupId":"BG000","value":"12"}],"units":"Participants"}],"groups":[{"description":"Pembrolizumab\n\nPembrolizumab: 200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or after 52 weeks of therapy.","id":"BG000","title":"Experimental Arm"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"12"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"27","upperLimit":"55","value":"38"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"12"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"12"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"11"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}],"title":"Testis"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Retroperitoneum"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Mediastinum"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Location Of Primary Tumor","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Seminoma"},{"measurements":[{"groupId":"BG000","value":"12"}],"title":"Nonseminoma"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Tumor Histology","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Choriocarcinoma"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Embryonal carcinoma"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Teratoma"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Yolk sac tumor"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Predominant Histology","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"3"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"4"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"5"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"6"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Number of Previous Chemotherapy Regimens","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}],"title":"ECOG 0"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"ECOG 1"}]}],"description":"Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) from 0-5 that describes a patient's level of functioning where 0=Fully active, able to carry on all pre-disease performance without restriction and 5=Dead","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Retroperitoneum"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Pulmonary"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Non Pulmonary Visceral Metastasis"}],"description":"The overall count of metastatic location(s). Subjects may have metastasis at multiple locations.","paramType":"NUMBER","title":"Metastatic Site(s)","unitOfMeasure":"participants"}]}